Verastem Inc. (VSTM) 1.30 $VSTM
Verastem to Present at Upcoming Investor Conferences
BusinessWire - Wed Jun 01, 6:00AM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the following upcoming investor conferences:
VSTM: 1.30 (-0.04)
Verastem Reports First Quarter 2016 Financial Results
BusinessWire - Mon May 09, 3:05PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the first quarter ended March 31, 2016, and also provided an overview of certain corporate developments.
VSTM: 1.30 (-0.04), MRK: 56.18 (-1.50)
Verastem Announces the Presentation of Clinical Data at iMig 2016
BusinessWire - Tue May 03, 8:15AM CDT
--- Results from Cohort 2 continue encouraging observations from Cohort 1 for single-agent VS-6063 in chemotherapy-naive patients as a neoadjuvant therapy -
VSTM: 1.30 (-0.04)
4 Trending Small Cap Stocks That You Need To Watch Today
ACCESSWIRE - Tue Apr 26, 7:27AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. LPTN, TLOG, HTM and VSTM are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
VSTM: 1.30 (-0.04), HTM: 0.80 (+0.01), LPTN: 2.16 (-0.20), TLOG: 0.33 (+0.01)
Verastem Names Gregory I. Berk, MD as Chief Medical Officer
BusinessWire - Mon Apr 18, 4:20PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the appointment of Gregory I. Berk, MD as Chief Medical Officer. Dr. Berk will be responsible for leading the Company's global clinical development strategy and clinical operations. Dr. Berk replaces interim Chief Medical Officer, Lou Vaickus, MD, FACP, from aktaPD who will continue to serve Verastem as a consultant.
VSTM: 1.30 (-0.04), MRK: 56.18 (-1.50)
Verastem Co-Founder, Dr. Robert Weinberg, Recognized with Two Prestigious Cancer Research Awards
BusinessWire - Mon Apr 18, 6:00AM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that Robert Weinberg, Ph.D., Verastem Co-founder and Chairman of the Scientific Advisory Board, and a pioneer in cancer research, was recently honored with the Salk Institute Medal for Research Excellence and the 13th annual American Association of Cancer Research (AACR) Lifetime Achievement Award for Cancer Research.
VSTM: 1.30 (-0.04)
Verastem Announces Presentation of Scientific Data Supporting FAK Inhibition in Combination with Immunotherapy at the Keystone Symposium on Cancer Pathophysiology
BusinessWire - Wed Mar 30, 3:05PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the oral presentation of preclinical data by the Company's scientific collaborator David G. DeNardo, PhD, Assistant Professor of Medicine, Division of Oncology, Department of Immunology, Washington University School of Medicine in St. Louis, at the Keystone Symposium on Cancer Pathophysiology being held March 28 - April 1, 2016 in Breckenridge, CO.
VSTM: 1.30 (-0.04)
Verastem Announces Oral Presentation of Data Supporting the Preferential Targeting of Ovarian Cancer Stem Cells at the Society of Gynecologic Oncology's 2016 Annual Meeting on Women's Cancer
BusinessWire - Tue Mar 22, 3:05PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of scientific data at the Society of Gynecologic Oncology's 2016 Annual Meeting on Women's Cancer being held March 19-22, 2016 in San Diego, CA.
VSTM: 1.30 (-0.04)
Verastem to Present Scientific Data Supporting FAK and PI3K/mTOR Inhibition to Target Cancer Stem Cells at the Keystone Symposium on Stem Cells and Cancer
BusinessWire - Thu Mar 10, 6:00AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of preclinical data and participation in an expert panel at the Keystone Symposium on Stem Cells and Cancer being held March 6 - 10, 2016 in Breckenridge, CO.
VSTM: 1.30 (-0.04)
Verastem to Present at 28th Annual ROTH Conference
BusinessWire - Tue Mar 08, 6:00AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the Company will present at the 28th Annual ROTH Conference on Tuesday, March 15 at 12:00 p.m. PT at the Ritz-Carlton in Dana Point, CA.
VSTM: 1.30 (-0.04)
Verastem, Inc. (NASDAQ: VSTM) Analyst Coverage Initiated
ACCESSWIRE - Mon Mar 07, 7:42AM CST
NEEDHAM, MA / ACCESSWIRE / March 7, 2016 / Verastem, Inc. (NASDAQ: VSTM) a company focused on discovering and developing drugs to treat cancer, recently reported financial results for the year ended December 31, 2015, and also provided an overview of certain corporate developments. "We are developing treatments that reduce cancer stem cells and modulate the local tumor microenvironment to allow both cancer treatments and the immune system to do their job more efficiently," said Robert Forrester, President and Chief Executive Officer of Verastem. "Our recently announced collaborations with Pfizer and Merck KGaA, and with Merck & Co. and Washington University in St. Louis, to evaluate the combination of our FAK inhibitors with immune-oncology agents speak to the understanding among the clinical community that innovative combination therapies have the potential to complement and enhance existing therapies. We begin 2016 with a strong balance sheet and expect significant progress from our ongoing programs targeting high unmet need cancers including non-small cell lung, ovarian, lymphoma, mesothelioma and pancreatic cancer. We are also planning for several trial initiations this year and we look forward to keeping you updated on our progress."
VSTM: 1.30 (-0.04), MRK: 56.18 (-1.50)
Pfizer, Merck KGaA, Verastem Ovarian Cancer Study Tie-Up
Zacks Equity Research - Zacks Investment Research - Fri Mar 04, 3:00PM CST
Pfizer (PFE), Merck KGaA and Verastem tie up to evaluate avelumab in combination with VS-6063 for the treatment of ovarian cancer.
VSTM: 1.30 (-0.04), SNDX: 11.02 (-0.50), PFE: 34.24 (-0.35)
Merck, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
BusinessWire - Thu Mar 03, 6:15AM CST
Merck, Pfizer and Verastem announced today that they have entered into an agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's VS-6063**, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanced ovarian cancer. Avelumab is currently under clinical investigation across a broad range of tumor types. The Phase I/Ib clinical trial is expected to begin in the second half of 2016. Financial terms of the agreement have not been disclosed.
VSTM: 1.30 (-0.04), PFE: 34.24 (-0.35), MRK: 56.18 (-1.50)
Verastem Reports Year-End 2015 Financial Results
BusinessWire - Thu Mar 03, 6:05AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the year ended December 31, 2015, and also provided an overview of certain corporate developments.
VSTM: 1.30 (-0.04)
Merck KGaA, Darmstadt, Germany, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
BusinessWire - Thu Mar 03, 6:00AM CST
Merck KGaA, Darmstadt, Germany, Pfizer and Verastem announced today that they have entered into an agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's VS-6063**, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanced ovarian cancer. Avelumab is currently under clinical investigation across a broad range of tumor types. The Phase I/Ib clinical trial is expected to begin in the second half of 2016. Financial terms of the agreement have not been disclosed.
VSTM: 1.30 (-0.04), PFE: 34.24 (-0.35)
Verastem to Present at Upcoming Investor Conferences
BusinessWire - Wed Jun 01, 6:00AM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the following upcoming investor conferences:
VSTM: 1.30 (-0.04)
Verastem Reports First Quarter 2016 Financial Results
BusinessWire - Mon May 09, 3:05PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the first quarter ended March 31, 2016, and also provided an overview of certain corporate developments.
VSTM: 1.30 (-0.04), MRK: 56.18 (-1.50)
Verastem Announces the Presentation of Clinical Data at iMig 2016
BusinessWire - Tue May 03, 8:15AM CDT
--- Results from Cohort 2 continue encouraging observations from Cohort 1 for single-agent VS-6063 in chemotherapy-naive patients as a neoadjuvant therapy -
VSTM: 1.30 (-0.04)
4 Trending Small Cap Stocks That You Need To Watch Today
ACCESSWIRE - Tue Apr 26, 7:27AM CDT
NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. LPTN, TLOG, HTM and VSTM are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
VSTM: 1.30 (-0.04), HTM: 0.80 (+0.01), LPTN: 2.16 (-0.20), TLOG: 0.33 (+0.01)
Verastem Names Gregory I. Berk, MD as Chief Medical Officer
BusinessWire - Mon Apr 18, 4:20PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the appointment of Gregory I. Berk, MD as Chief Medical Officer. Dr. Berk will be responsible for leading the Company's global clinical development strategy and clinical operations. Dr. Berk replaces interim Chief Medical Officer, Lou Vaickus, MD, FACP, from aktaPD who will continue to serve Verastem as a consultant.
VSTM: 1.30 (-0.04), MRK: 56.18 (-1.50)
Verastem Co-Founder, Dr. Robert Weinberg, Recognized with Two Prestigious Cancer Research Awards
BusinessWire - Mon Apr 18, 6:00AM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that Robert Weinberg, Ph.D., Verastem Co-founder and Chairman of the Scientific Advisory Board, and a pioneer in cancer research, was recently honored with the Salk Institute Medal for Research Excellence and the 13th annual American Association of Cancer Research (AACR) Lifetime Achievement Award for Cancer Research.
VSTM: 1.30 (-0.04)
Verastem Announces Presentation of Scientific Data Supporting FAK Inhibition in Combination with Immunotherapy at the Keystone Symposium on Cancer Pathophysiology
BusinessWire - Wed Mar 30, 3:05PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the oral presentation of preclinical data by the Company's scientific collaborator David G. DeNardo, PhD, Assistant Professor of Medicine, Division of Oncology, Department of Immunology, Washington University School of Medicine in St. Louis, at the Keystone Symposium on Cancer Pathophysiology being held March 28 - April 1, 2016 in Breckenridge, CO.
VSTM: 1.30 (-0.04)
Verastem Announces Oral Presentation of Data Supporting the Preferential Targeting of Ovarian Cancer Stem Cells at the Society of Gynecologic Oncology's 2016 Annual Meeting on Women's Cancer
BusinessWire - Tue Mar 22, 3:05PM CDT
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of scientific data at the Society of Gynecologic Oncology's 2016 Annual Meeting on Women's Cancer being held March 19-22, 2016 in San Diego, CA.
VSTM: 1.30 (-0.04)
Verastem to Present Scientific Data Supporting FAK and PI3K/mTOR Inhibition to Target Cancer Stem Cells at the Keystone Symposium on Stem Cells and Cancer
BusinessWire - Thu Mar 10, 6:00AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of preclinical data and participation in an expert panel at the Keystone Symposium on Stem Cells and Cancer being held March 6 - 10, 2016 in Breckenridge, CO.
VSTM: 1.30 (-0.04)
Verastem to Present at 28th Annual ROTH Conference
BusinessWire - Tue Mar 08, 6:00AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the Company will present at the 28th Annual ROTH Conference on Tuesday, March 15 at 12:00 p.m. PT at the Ritz-Carlton in Dana Point, CA.
VSTM: 1.30 (-0.04)
Verastem, Inc. (NASDAQ: VSTM) Analyst Coverage Initiated
ACCESSWIRE - Mon Mar 07, 7:42AM CST
NEEDHAM, MA / ACCESSWIRE / March 7, 2016 / Verastem, Inc. (NASDAQ: VSTM) a company focused on discovering and developing drugs to treat cancer, recently reported financial results for the year ended December 31, 2015, and also provided an overview of certain corporate developments. "We are developing treatments that reduce cancer stem cells and modulate the local tumor microenvironment to allow both cancer treatments and the immune system to do their job more efficiently," said Robert Forrester, President and Chief Executive Officer of Verastem. "Our recently announced collaborations with Pfizer and Merck KGaA, and with Merck & Co. and Washington University in St. Louis, to evaluate the combination of our FAK inhibitors with immune-oncology agents speak to the understanding among the clinical community that innovative combination therapies have the potential to complement and enhance existing therapies. We begin 2016 with a strong balance sheet and expect significant progress from our ongoing programs targeting high unmet need cancers including non-small cell lung, ovarian, lymphoma, mesothelioma and pancreatic cancer. We are also planning for several trial initiations this year and we look forward to keeping you updated on our progress."
VSTM: 1.30 (-0.04), MRK: 56.18 (-1.50)
Pfizer, Merck KGaA, Verastem Ovarian Cancer Study Tie-Up
Zacks Equity Research - Zacks Investment Research - Fri Mar 04, 3:00PM CST
Pfizer (PFE), Merck KGaA and Verastem tie up to evaluate avelumab in combination with VS-6063 for the treatment of ovarian cancer.
VSTM: 1.30 (-0.04), SNDX: 11.02 (-0.50), PFE: 34.24 (-0.35)
Merck, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
BusinessWire - Thu Mar 03, 6:15AM CST
Merck, Pfizer and Verastem announced today that they have entered into an agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's VS-6063**, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanced ovarian cancer. Avelumab is currently under clinical investigation across a broad range of tumor types. The Phase I/Ib clinical trial is expected to begin in the second half of 2016. Financial terms of the agreement have not been disclosed.
VSTM: 1.30 (-0.04), PFE: 34.24 (-0.35), MRK: 56.18 (-1.50)
Verastem Reports Year-End 2015 Financial Results
BusinessWire - Thu Mar 03, 6:05AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the year ended December 31, 2015, and also provided an overview of certain corporate developments.
VSTM: 1.30 (-0.04)
Merck KGaA, Darmstadt, Germany, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer
BusinessWire - Thu Mar 03, 6:00AM CST
Merck KGaA, Darmstadt, Germany, Pfizer and Verastem announced today that they have entered into an agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's VS-6063**, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanced ovarian cancer. Avelumab is currently under clinical investigation across a broad range of tumor types. The Phase I/Ib clinical trial is expected to begin in the second half of 2016. Financial terms of the agreement have not been disclosed.
VSTM: 1.30 (-0.04), PFE: 34.24 (-0.35)
